NCT04423029 2026-03-18
A Study of DF6002 Alone and in Combination With Nivolumab
Dragonfly Therapeutics
Phase 1 Completed
Clinical Trials
1,065 trialsNCT06108479 2026-03-18
Study of DF6215 in Patients With Advanced Solid Tumors
Dragonfly Therapeutics
Phase 1 Completed
NCT03070392 2026-03-17
Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma
Immunocore Ltd
Phase 2 Completed
NCT04609566 2026-03-16
Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors
Seagen Inc.
Phase 2 Completed
NCT02410733 2026-03-12
Lipo-MERIT
BioNTech SE
Phase 1 Completed
NCT03239145 2026-03-12
Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor
Dana-Farber Cancer Institute
Phase 1 Completed
NCT02858869 2026-03-09
Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases
Emory University
Phase 1 Completed
NCT05199584 2026-03-05
A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
Endeavor Biomedicines, Inc.
Phase 2 Completed
NCT04335890 2026-03-04
IKKb-matured, RNA-loaded Dendritic Cells for Metastasised Uveal Melanoma
Hasumi International Research Foundation
Phase 1 Completed
NCT07436390 2026-03-02
MAK
Institute of Oncology Ljubljana
Phase NA Completed
NCT01909453 2026-02-27
COLUMBUS
Pfizer
Phase 3 Completed
NCT02645149 2026-02-27
Match Mel
Melanoma Institute Australia
Phase 2 Completed
NCT03501368 2026-02-27
Study of Trametinib + Ceritinib in Patients With Unresectable Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT05907122 2026-02-27
A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Melanoma
Amgen
Phase 3 Completed
NCT07434323 2026-02-25
LAPAM
San Gallicano Dermatological Institute IRCCS
Phase NA Completed
NCT03400332 2026-02-24
A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers
Bristol-Myers Squibb
Phase 1/2 Completed
NCT07422805 2026-02-24
ctDNA
Institute of Oncology Ljubljana
Phase NA Completed
NCT07431489 2026-02-24
Retinal Structural and Functional Changes in Patients Treated With BRAF/MEK Inhibitors
Institute of Oncology Ljubljana
Phase NA Completed
NCT01659151 2026-02-20
Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT04526730 2026-02-20
Neoadjuvant Immunotherapy With Tavo + Electroporation in Combination With Nivo. in Melanoma Patients
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT03820986 2026-02-09
LEAP-003
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT01625351 2026-02-06
A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas
St. Jude Children's Research Hospital
Phase 1 Completed
NCT02989064 2026-02-04
MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck Cancers
Adaptimmune
Phase 1 Completed
NCT05419388 2026-02-04
A Study of Multiple Doses of RO7247669 in Participants With Previously Untreated Unresectable or Metastatic Melanoma
Hoffmann-La Roche
Phase 2 Completed
NCT03756792 2026-01-29
Assessing Patient Anxiety During Mohs Micrographic Surgery
Wake Forest University Health Sciences
Phase NA Completed
NCT02862743 2026-01-21
MELCIRC
CHU de Reims
Phase NA Completed
NCT04109456 2026-01-15
IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma
InxMed (Shanghai) Co., Ltd.
Phase 1 Completed
NCT03028948 2026-01-14
Interactive Tailored Website to Promote Sun Protection and Skin Self-Check Behaviors in Patients With Melanoma
Rutgers, The State University of New Jersey
Phase NA Completed
NCT02975700 2026-01-13
A Study of PLX3397 in Patients With Unresectable or Metastatic KIT-mutated Melanoma
Daiichi Sankyo
Phase NA Completed
NCT03873818 2026-01-09
Low Dose Ipilimumab With Pembrolizumab in Treating Patients With Melanoma That Has Spread to the Brain
M.D. Anderson Cancer Center
Phase 2 Completed
NCT04526899 2026-01-08
A Study to Investigate the Novel Agent BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Advanced Melanoma That Has Not Responded to Other Forms of Treatment
BioNTech SE
Phase 2 Completed
NCT03405155 2025-12-31
Nivolumab in Treating Patients With Stage IIB-IIC Melanoma That Can Be Removed by Surgery
Thomas Jefferson University
Phase 2 Completed
NCT02917473 2025-12-30
FADEMELA
University Hospital, Tours
Phase NA Completed
NCT03993678 2025-12-30
Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With Advanced Solid Tumors.
Swiss Cancer Institute
Phase 1/2 Completed
NCT01970358 2025-12-29
A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in Melanoma
Dana-Farber Cancer Institute
Phase 1 Completed
NCT04889118 2025-12-23
LEAP-003
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT06120712 2025-12-23
MIZAR-002
Shanghai Juncell Therapeutics
Phase 1/2 Completed
NCT01005745 2025-12-19
Lymphodepletion Plus Adoptive Cell Transfer With High Dose IL-2 in Patients With Metastatic Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase NA Completed
NCT01319565 2025-12-19
Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Tumor Infiltrating Lymphocytes Plus IL-2 Following Non-Myeloablative Lymphocyte Depleting Chemo Regimen Alone or in Conjunction With 12Gy Total Body Irradiation (TBI...
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01701674 2025-12-19
Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts
H. Lee Moffitt Cancer Center and Research Institute
Phase NA Completed
NCT03509467 2025-12-19
Using MC1R Genotype to Impact Melanoma Risk Behavior
H. Lee Moffitt Cancer Center and Research Institute
Phase NA Completed
NCT01950390 2025-12-11
Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT04157985 2025-12-11
Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
University of Pittsburgh
Phase 3 Completed
NCT02360579 2025-12-09
LN-144
Iovance Biotherapeutics, Inc.
Phase 2 Completed
NCT05675709 2025-12-08
Enhancing Skin Cancer Early Detection and Treatment in Primary Care
OHSU Knight Cancer Institute
Phase NA Completed
NCT04570332 2025-11-26
SPOTLIGHT203
Highlight Therapeutics
Phase 2 Completed
NCT02639026 2025-11-25
Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers
Abramson Cancer Center at Penn Medicine
Phase 1 Completed
NCT05668585 2025-11-21
A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors
C4 Therapeutics, Inc.
Phase 1 Completed
NCT04796194 2025-11-20
ATLAS-IT-05
Lytix Biopharma AS
Phase 2 Completed
NCT01473004 2025-11-14
SIR-Spheres® 90Y Microspheres Treatment of Uveal Melanoma Metastasized to Liver
Thomas Jefferson University
Phase 2 Completed